Incyte & Lilly's Olumiant Gets Marketing Approval in Japan

Shutterstock photo

Incyte Corporation INCY and partner Eli Lilly and Company LLY announced that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant (baricitinib) 2-mg and 4-mg tablets. The drug will be used for treating rheumatoid arthritis (RA) (including the prevention of structural injury of joints) in patients with inadequate response to standard-of-care therapies.

Olumiant demonstrated significant improvement in the signs and symptoms of RA compared to standard-of-care therapies.

The approval triggers a $15 million milestone payment from Eli Lilly to Incyte, which the latter expects to recognize in the third quarter of 2017.

The move is likely to boost sales of Olumiant. Approximately 700,000-800,000 people suffer from RA and women are three times more likely to be affected than men.Thus, there is substantial demand for such drugs.

The approval provides Incyte with a valuable source of revenues, given the potential for milestones and royalties under the company's license agreement with Eli Lilly. Olumiant is being studied for additional indications as well - atopic dermatitis (phase IIa) and systemic lupus erythematosus (phase II). We remind investors that both Lilly and Incyte announced an exclusive worldwide license and collaboration agreement in Dec 2009 for the development and commercialization of Olumiant and certain follow-on compounds for patients with inflammatory and autoimmune diseases. The drug was approved in the EU in Feb 2017.

However, in Apr 2017, Incyte received a Complete Response Letter (CRL) from the FDA for Olumiant. The FDA requires additional clinical data, which will delay the approval of the drug. The FDA had earlier extended the review period as well. The company suffered a major setback due to the delay.

Incyte's shares have rallied 25.5% year to date, while the Zacks classified Medical - Biomedical and Genetics industry gained 6.4%.

Incyte's growth driver Jakafi continues to drive growth. The increase in Jakafi sales is driven by patient demand and is expected to boost revenues. While most of the demand is due to a larger established patient base in myelofibrosis, polycythemia vera is also expected to be a major long-term driver of Jakafi growth. While Incyte markets the drug in the U.S., it is marketed by Novartis NVS as Jakavi outside the U.S. An approval of Olumiant in other countries will boost Incyte's top line.

We note that Incyte has collaborated with Merck MRK among others for another candidate in its pipeline -epacadostat.

Zacks Rank

Incyte currently carries a Zacks Rank #3 (Hold). You can see  the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Novartis AG (NVS): Free Stock Analysis Report

Merck & Company, Inc. (MRK): Free Stock Analysis Report

Incyte Corporation (INCY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Symbols: LLY , NVS , MRK , INCY

More from Zacks.com




Equity Research

Research Brokers before you trade

Want to trade FX?